BrainsWay Ltd. (TLV:BWAY)

Market Cap	1.93B +192.7%
Revenue (ttm)	166.49M +27.3%
Net Income	24.15M +159.3%
EPS	0.58 +229.1%
Shares Out	40.03M
PE Ratio	82.99
Forward PE	53.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,688
Average Volume	86,504
Open	4,844.00
Previous Close	4,821.00
Day's Range	4,686.00 - 4,844.00
52-Week Range	1,498.00 - 5,026.00
Beta	0.14
RSI	62.85
Earnings Date	May 13, 2026

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2003
• Employees: 120
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BWAY

Financial Performance

In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.

Financial numbers in USD